Accelerating Rare Liver Disease Study Enrollment

An emerging clinical stage biotech contracted with EVERSANA to conduct Phase II trial enrollment support for an ultra-rare liver disease through our Seeker Health platform. Because of the ultra-rare patient population and nature of the therapy, the client expected significant recruitment challenges.

Read more, download the full case study: Accelerating Rare Liver Disease Study Enrollment

Learn more about Seeker Health® by EVERSANA! Contact us to learn how we can help you to identify and engage with even the most difficult-to-reach patients for your clinical trial.

Author Team
Seeker Health

Seeker Health by EVERSANA is a digital health platform helping biopharmaceutical companies connect with patients in need of clinical trials. Through a wide array of digital strategies, we work to make access to clinical trials and early stage drugs easier for patient and their families. Learn more about Seeker Health